JP7698418B2 - Egfr活性化変異を有するがんを治療するための方法 - Google Patents

Egfr活性化変異を有するがんを治療するための方法 Download PDF

Info

Publication number
JP7698418B2
JP7698418B2 JP2020548775A JP2020548775A JP7698418B2 JP 7698418 B2 JP7698418 B2 JP 7698418B2 JP 2020548775 A JP2020548775 A JP 2020548775A JP 2020548775 A JP2020548775 A JP 2020548775A JP 7698418 B2 JP7698418 B2 JP 7698418B2
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
pharmaceutical composition
egfr
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020548775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517894A (ja
JP2021517894A5 (cg-RX-API-DMAC7.html
Inventor
ジョン ブイ. ヘイマッハ
モニーク ニルソン
ジャクリーン ロビショー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2021517894A publication Critical patent/JP2021517894A/ja
Publication of JP2021517894A5 publication Critical patent/JP2021517894A5/ja
Priority to JP2025013551A priority Critical patent/JP2025069282A/ja
Application granted granted Critical
Publication of JP7698418B2 publication Critical patent/JP7698418B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020548775A 2018-03-13 2019-03-13 Egfr活性化変異を有するがんを治療するための方法 Active JP7698418B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013551A JP2025069282A (ja) 2018-03-13 2025-01-30 Egfr活性化変異を有するがんを治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642472P 2018-03-13 2018-03-13
US62/642,472 2018-03-13
PCT/US2019/022067 WO2019178239A1 (en) 2018-03-13 2019-03-13 Methods for treatment of cancers with egfr activating mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013551A Division JP2025069282A (ja) 2018-03-13 2025-01-30 Egfr活性化変異を有するがんを治療するための方法

Publications (3)

Publication Number Publication Date
JP2021517894A JP2021517894A (ja) 2021-07-29
JP2021517894A5 JP2021517894A5 (cg-RX-API-DMAC7.html) 2022-03-22
JP7698418B2 true JP7698418B2 (ja) 2025-06-25

Family

ID=67908486

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548775A Active JP7698418B2 (ja) 2018-03-13 2019-03-13 Egfr活性化変異を有するがんを治療するための方法
JP2025013551A Withdrawn JP2025069282A (ja) 2018-03-13 2025-01-30 Egfr活性化変異を有するがんを治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013551A Withdrawn JP2025069282A (ja) 2018-03-13 2025-01-30 Egfr活性化変異を有するがんを治療するための方法

Country Status (5)

Country Link
US (1) US20210015819A1 (cg-RX-API-DMAC7.html)
JP (2) JP7698418B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200132902A (cg-RX-API-DMAC7.html)
CN (1) CN111867586A (cg-RX-API-DMAC7.html)
WO (1) WO2019178239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105816437B (zh) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
US20220143023A1 (en) * 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
EP4192463A1 (en) * 2020-08-07 2023-06-14 Hope Permanente, LLC Use of cyclin-dependent kinase (cdk) inhibitors for the slowdown or prevention of biological aging
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN117460843A (zh) * 2021-01-29 2024-01-26 德克萨斯大学系统董事会 用激酶抑制剂治疗癌症的方法
CN114432454B (zh) * 2022-03-21 2023-05-05 安徽大学 Plk1抑制剂在制备治疗埃博拉病毒疾病的药物中的应用
US12275738B2 (en) 2022-04-08 2025-04-15 Biolexis Therapeutics, Inc. CDK9 inhibitors
CN117045660A (zh) * 2022-04-22 2023-11-14 南京市儿童医院 一种plk1抑制剂在制备用于缓解肾脏纤维化药物中的用途
WO2024192141A1 (en) * 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
CN117860753A (zh) * 2023-11-30 2024-04-12 华中科技大学 一种cdc7抑制剂化合物xl413在制备预防或治疗肝损伤和肝纤维化药物及应用
WO2025245045A1 (en) * 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528695A (ja) 2005-02-03 2008-07-31 ザ ジェネラル ホスピタル コーポレーション ゲフィチニブ耐性癌を治療する方法
JP2009526009A (ja) 2006-02-10 2009-07-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Cdk阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ
JP2010523536A (ja) 2007-04-04 2010-07-15 サイクラセル リミテッド プリンに基づくcdk阻害剤とチロシンキナーゼ阻害剤の組合せ、及び増殖性障害の治療におけるその使用
US20110033461A1 (en) 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
JP2013519707A (ja) 2010-02-19 2013-05-30 ノバルティス アーゲー Cdk4/6阻害剤としてのピロロピリミジン化合物
JP2014141530A (ja) 2007-04-13 2014-08-07 Dana Farber Cancer Institute Inc ErbB療法に耐性である癌を治療するための方法
JP2018090566A (ja) 2016-11-16 2018-06-14 ファイザー・インク 非小細胞肺癌の治療のためのegfr t790m阻害剤およびcdk阻害剤の組合せ

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5474354B2 (ja) * 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2224919A4 (en) * 2007-11-28 2011-09-14 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND TUMOR-RELATED DISEASES
WO2012135841A2 (en) * 2011-04-01 2012-10-04 Board Of Regents, The University Of Texas System Emt signatures and predictive markers and method of using the same
WO2013158859A1 (en) * 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
BR102013027577A2 (pt) * 2012-10-25 2016-03-29 Memorialsloan Kettering Cancer Ct método de detecção de um nível aumentado de axl ou gas6 e método de identificação de um paciente com câncer resistente a inibidor de egfr
US11013743B2 (en) * 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
WO2015112705A2 (en) * 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
US20160346240A1 (en) * 2014-02-03 2016-12-01 Quadriga Biosciences, Inc. Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs
EP3148532B1 (en) * 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
CA2986441A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10240145B2 (en) * 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
GB201612520D0 (en) * 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
CA3076023C (en) * 2017-11-06 2026-04-07 Tiziana Life Sciences Plc Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528695A (ja) 2005-02-03 2008-07-31 ザ ジェネラル ホスピタル コーポレーション ゲフィチニブ耐性癌を治療する方法
JP2009526009A (ja) 2006-02-10 2009-07-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Cdk阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ
JP2010523536A (ja) 2007-04-04 2010-07-15 サイクラセル リミテッド プリンに基づくcdk阻害剤とチロシンキナーゼ阻害剤の組合せ、及び増殖性障害の治療におけるその使用
JP2014141530A (ja) 2007-04-13 2014-08-07 Dana Farber Cancer Institute Inc ErbB療法に耐性である癌を治療するための方法
US20110033461A1 (en) 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
JP2013519707A (ja) 2010-02-19 2013-05-30 ノバルティス アーゲー Cdk4/6阻害剤としてのピロロピリミジン化合物
JP2018090566A (ja) 2016-11-16 2018-06-14 ファイザー・インク 非小細胞肺癌の治療のためのegfr t790m阻害剤およびcdk阻害剤の組合せ

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cancer Res, 2006, Vol.66, No.23, pp.11389-11398,doi:10.1158/0008-5472.CAN-06-2318
Ching-Chuan Ku, et al.,Mol. Cancer Ther.,Abstract A171: Targeting tumor metabolism by novel EGFR inhibitor in head and neckcancer,2015年,Vol.14, No.12, Supplement_2,Abstract No.A171,https://doi.org/10.1158/1535-7163.TARG-15-A171
Journal of Thoracic Oncology, 2017, Vol.12, No.11S1, p.S1582
Molecular Cancer Therapeutics, 2012, Vol.Vol.11, No.1, pp.204-213,doi: 10.1158/1535-7163.MCT-11-0638

Also Published As

Publication number Publication date
KR20200132902A (ko) 2020-11-25
JP2021517894A (ja) 2021-07-29
CN111867586A (zh) 2020-10-30
JP2025069282A (ja) 2025-04-30
US20210015819A1 (en) 2021-01-21
WO2019178239A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
JP7685550B2 (ja) Egfrまたはher2のエクソン20変異を有するがん細胞に対する抗腫瘍活性を有する化合物
JP2025069282A (ja) Egfr活性化変異を有するがんを治療するための方法
JP7709384B2 (ja) チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
JP7822597B2 (ja) チロシンキナーゼ阻害剤耐性egfr変異を有するがん細胞に対する抗腫瘍活性を有する化合物
JP7700043B2 (ja) Her2エクソン21挿入を有するがん細胞に対する抗腫瘍活性を有する化合物
JP7386174B2 (ja) Her2エクソン19変異を有するがん細胞に対する抗腫瘍活性を有する化合物
CN115698717A (zh) 癌症的治疗和诊断方法
HK40039581A (en) Methods for treatment of cancers with egfr activating mutations
HK40013571B (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations
HK40064296A (en) Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
HK40064724A (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
EA041212B1 (ru) Соединения с противоопухолевой активностью в отношении раковых клеток, несущих мутации в 20 экзоне egfr или her2

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231214

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250321

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250613

R150 Certificate of patent or registration of utility model

Ref document number: 7698418

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150